Biopharmaceutical Drug Design and Development - Authoritative

Our review of Biopharmaceutical Drug Design and Development finds it best suited for graduate students, researchers, and professionals needing a comprehensive update on biologic therapeutics since 1999. This second edition collects expanded chapters that examine dozens of new biopharmaceuticals and emerging technologies, making it a useful reference for those tracking clinical and regulatory trends. The single biggest reason to buy is its breadth: the book brings together discussion of monoclonal antibodies, cytokines, gene delivery, and FDA approval changes in one place, serving as a compact bridge between classic principles and modern advances.

Key Features

• Coverage of new biopharmaceuticals: Discusses dozens of biologic drugs introduced since the first edition, helping readers understand recent therapeutic classes and examples.
• Therapeutic categories: Reviews monoclonal antibodies, cytokines, growth factors, enzymes, immunomodulators, and thrombolytics to illustrate diverse clinical uses.
• Emerging technologies: Explores bioinformatics, DNA microarrays, transgenics, therapeutic gene delivery, and stem cells to show where the field is headed.
• Nucleic acid and macromolecular delivery: Examines nucleic acid-based therapeutics and macromolecular drug delivery with practical context for formulation and targeting challenges.
• Clinical and regulatory perspective: Looks at pharmacogenetics in the clinic and changes in biologic drug approval at the FDA to connect science with practice and policy.

Who It's For

This book is aimed at graduate students in biological sciences, researchers in academic or industry labs, and clinicians who need a broad but informed review of biologic drug classes and the technologies behind them. The scope is especially helpful for those designing studies or seeking context for therapeutic development decisions.

It is less suited for casual readers or for professionals seeking step-by-step laboratory protocols; the text focuses on conceptual, clinical, and regulatory surveys rather than hands-on methods or brief overviews confined to a single therapeutic area.

Pros & Cons

Pros

• Comprehensive updates gather many new biopharmaceuticals into one reference for comparative study.
• Balanced mix of therapeutic categories and emerging technologies provides multidisciplinary perspective.
• Includes regulatory and pharmacogenetic discussion that links laboratory advances to clinical implementation.

Cons

• Not a lab manual; readers looking for detailed experimental protocols should consult specialized technique texts.

Specifications

Title	Biopharmaceutical Drug Design and Development, Second Edition
Authors	Susanna Wu-Pong, Yon Rojanasakul
Edition	Second Edition (expanded from 1999)
Subject	Biopharmaceuticals, therapeutic biologics, and development technologies
Topics included	Monoclonal antibodies, cytokines, growth factors, enzymes, immunotherapies, vaccines
Technologies discussed	Bioinformatics, DNA microarrays, transgenics, gene delivery, stem cells, nucleic acid therapeutics
Regulatory focus	Pharmacogenetics and FDA biologic approval changes

Our Verdict

Biopharmaceutical Drug Design and Development is a solid, value-packed reference for researchers and advanced students who need an integrated account of modern biologic therapeutics and enabling technologies. Its wide topical reach and regulatory context make it particularly useful for interdisciplinary teams and those monitoring the evolution of drug approval and clinical application.

Frequently Asked Questions

Does this edition cover monoclonal antibodies?
Yes; the book reviews monoclonal antibodies for in-vivo use along with other major biologic classes.

Is the book practical for lab bench protocols?
No; it is written as a conceptual and clinical review rather than a step-by-step laboratory manual.

Does it address regulatory changes?
Yes; the authors discuss changes in FDA biologic approval processes and the clinical implications of pharmacogenetics.